BioSpace News Archive

The IPO is an offer by Telix for the issue of 77.0 million shares at $0.65 per share and is fully underwritten by the Lead Managers, Taylor Collison Limited and Wilsons Corporate Finance Limited

SGX-Listed Singapore eDevelopment Ltd (“Sed”) announced today that U.S. biomedical subsidiary Global BioLife Inc. has developed a breakthrough low-calorie, low glycemic index, natural, modified sugar Laetose.

For 20 years, Kibow Biotech has been refining a novel approach to maintaining healthy kidney function “Enteric Dialysis”. Enteric Dialysis utilizes probiotics (yes, probiotics) to metabolize the waste products (toxins) building up in the bloodstream due to reduced kidney function.

Bayer announced today that data from its pulmonary disease franchise will be presented in scientific sessions at the 2017 annual meeting of the American College of Chest Physicians (CHEST 2017), October 28 - November 1 in Toronto, Canada.

A team of researchers from the University of Maryland School of Pharmacy and the University of Maryland School of Medicinefound that current (prolonged) use of serotonin reuptake inhibitors – a major class of antidepressant medications – in children and adolescents was associated with a nearly two-fold increased risk of developing type 2 diabetes when compared to youths who formerly used (but eventually discontinued) those medications.

Microsoft Corp. and PAREXEL International Corp., a leading global biopharmaceutical services organization, on Tuesday announced a technology development alliance aimed at driving innovation across the life sciences industry with technology powered by Microsoft Azure.

The American Physical Society (APS) has awarded Rice University nanoscientist Naomi Halas the prestigious 2018 Julius Edgar Lilienfeld Prize.

Almac Clinical Technologies, a global leader in technology-enabled solutions for managing clinical trial patient and supplies data, has extended the functionality of its industry-leading IXRS 3 IRT platform to include Accountability and Reconciliation Tracking (ART).

Irvine-based Biogennix announced today that it is expanding its distribution efforts for its novel bone graft substitutes, Morpheus and osteoSPAN to full national distribution.

Moleculin Biotech announced that has submitted its request for Clinical Trial Authorization (“CTA”) in Poland which, if allowed, will enable a clinical trial to study Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (“AML”) in Poland.